Nyxoah SA, a medical technology company focused on developing solutions to treat obstructive sleep apnea (OSA), including the Genio neurostimulator, has partnered with ResMed Germany to increase OSA awareness and therapy penetration in the German market.
Nyxoah and ResMed Germany will establish a continuum of care that will educate and guide OSA patients in the German market from diagnosis through treatment. Together, the companies will work to accelerate patient identification and better support patient set-up on the appropriate therapy.
The companies will collaborate on:
- OSA helplines and direct-to-consumer marketing initiatives
- Sales and marketing efforts targeting ENTs and sleep physicians
- Patient and clinician educational programs and symposiums
“We are thrilled to partner with ResMed Germany, as it strengthens further our patient-first approach to treating obstructive sleep apnea. OSA reduces quality of life and can result in other serious medical conditions, such as cardiovascular disease and type 2 diabetes. Together, ResMed Germany and Nyxoah will heighten awareness of OSA and increase therapy penetration,” says Olivier Taelman, Nyxoah’s CEO, in a release. “The OSA ecosystem created by this partnership will guide patients from diagnosis to the right treatment for them, whether that is a mandibular device, continuous positive airway pressure, or hypoglossal nerve stimulation.”
Katrin Pucknat, president of ResMed Germany, adds in a release, “It is our joint goal to enable more patients to receive effective, personalized therapy. Over 95% of patients in Germany suffering from sleep apnea are not diagnosed or treated. In addition, there are patients who have problems with their therapy and just stop it without considering an alternative. The partnership with Nyxoah will enable us to broaden the education around therapy options and empower patients to benefit from improved health outcomes.”